<DOC>
	<DOCNO>NCT03062813</DOCNO>
	<brief_summary>This study evaluate efficacy safety Tacrolimus combine entecavir antiviral therapy HBV-associated glomerulonephritis china . Tacrolimus combine entecavir rapidly effectively induced remission HBV-GN Chinese adult . Meanwhile , Tacrolimus may synergistic antiviral effect entecavir . The study protocol review approve Guangdong General Hospital 's Ethic Committee , participant provide write informed consent . The study prospective , randomize , control , single-blind , multi-centre , withdrawal study conduct Guangdong general hospital , Guangdong Academy Medical Sciences.there two phase , phase 1 , Screening enrol 112 HBV-GN patient one year , phase 2 , ongoing follow-up 24 weeks.The data patient record HBV-GN electronic database.Before randomisation , All patient receive entecavir routine antiviral therapy two weeks.And randomize two different group , treatment group : Tacrolimus combine entecavir antiviral therapy , control group : The Tacrolimus placebo entecavir antiviral therapy . The Tacrolimus target trough concentration 5-10 ng/mL therapy . The primary outcome variable number patient reach complete partial remission ( CR PR ) 25 week-treatment . CR deﬁned &lt; 0.3 g/24 h proteinuria ( UPCR &lt; 300mg/g.cr ) low plus stable renal function ( eGFR &gt; 50 ml/min/1.73 m2 ) PR proteinuria 0.3-3.0 g/24 h ( UPCR 300-3000mg/g.cr ) 50 % low baseline proteinuria plus stable renal function . Secondary outcome variable : 1 ) The number patient reach complete partial remission ( CR PR ) 13 week-treatment . 2 ) Serum creatinine ( SCr ) increase 2 time baseline level 50 % low baseline eGFR ( accord chronic kidney disease-EPI ( CKD-EPI ) ) 25 week-treatment . 3 ) Serum HBV DNA undetectable ( HBV DNA &lt; 500copies/ml ) end 25 week-treatment . 4 ) The number patient present acute kidney injury end 25 week-treatment .</brief_summary>
	<brief_title>Tacrolimus Combined With Entecavir HBV Associated Glomerulonephritis ( HBV-GN )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Nephrotic Syndrome</mesh_term>
	<mesh_term>Nephrosis</mesh_term>
	<mesh_term>Glomerulonephritis</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>Male female patient age 18 65 year HBVGN ; All HBVGN case biopsyproven ; Evidence chronic HBV infection base presence HBsAg , HBeAg HBV DNA serum ; ( HBsAg , HBeAg positive , HBV DNA ≥10*3 IU/ml ) . Chronic HBV infection last six month , patient receive antiviral therapy past six month ; Proteinuria 3.0g/24h , UPCR &gt; 3000mg/g.cr , result proof least two test ; No glucocorticoid immunosuppressive treatment within previous 2 week . The diagnosis idiopathic membranous nephropathy ( MN ) , systemic lupus erythematosus , malignancy , diabetes mellitus , severe infection systemic disease know associated secondary MN ; eGFR &lt; 30ml/min.1.73m*2 ; Renal pathology show Tubular atrophy Interstitial fibrosis 50 % ; The participant allergy tacrolimus , entecavir ; History diabetes mellitus ; History severe heart disease cerebrovascular disease ; Other active infection cytomegalovirus ( CMV ) , Tuberculosis , Hepatitis A virus ( HAV ) , Hepatitis C virus ( HCV ) , Hepatitis D virus ( HDV ) ; Innate acquire immunodeficiency ; liver cirrhosis , liver malignment tumor ; Pregnant , try become pregnant breast feeding ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hepatitis B virus , tacrolimus , membranous nephropathy</keyword>
</DOC>